A new biomarker test can detect early-stage tau protein clumping up to a decade before it appears on brain scans, improving ...
More than 2 years since the original trial data for lecanemab in Alzheimer's disease was published,1 and over 1·5 years since approval by the US Food and Drug Administration, brain volume data have ...
In diseases like Parkinson's and Alzheimer's, specific proteins misfold and clump together, forming toxic aggregates that ...
In diseases like Parkinson's and Alzheimer's, specific proteins misfold and clump together, forming toxic aggregates that ...
Using a new animal model of Alzheimer’s disease, the study highlights a potential breakthrough in treatment strategies.
In diseases like Parkinson's and Alzheimer's, specific proteins misfold and clump together, forming toxic aggregates that damage brain ...
In diseases like Parkinson's and Alzheimer's, specific proteins misfold and clump together, forming toxic aggregates that ...
Scientists have identified a biomarker for Alzheimer's that may help doctors spot the early signs of protein buildup in the ...
In related news, other scientists recently reported that phospho-tau isoforms in the CSF mirror protofibrillar forms of tau, ...
Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback